Non-alcoholic Steatohepatitis (NASH) Clinical Trial
Official title:
Non-alcoholic Fatty Liver Disease Parametric PET (FLiPP) Study
The goal of this study is to evaluate non-invasive imaging techniques for determining liver steatosis (fat), inflammation (abnormal tissue swelling), and fibrosis (abnormal tissue scarring).In addition, the study group will be using other test measures including personal demographics, laboratory blood test results, and imaging measurements to determine the severity of NAFLD (non-alcoholic fatty liver disease), NASH (non-alcoholic steatohepatitis), inflammation, and fibrosis.
The study group proposes to evaluate the role of fluorodeoxyglucose (FDG) positron emission tomography (PET) in the determination of steatohepatitis and in combination with MRI for detection, differentiation and quantitation of liver steatosis, steatohepatitis and fibrosis in correlation to liver biopsy. Patient enrolled in this will already have had their liver biopsy or will be undergoing liver biopsy as a part of their clinical care as determined by their provider and will not be getting biopsies solely to be enrolled in the study. Current treatment options for patients that liver biopsy is being performed are limited to lifestyle changes and vitamin E for patients without diabetes. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04481594 -
A Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of HPN-01 in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT06151964 -
A Trial to Learn How Safe AZD9550 is in People With Type 2 Diabetes Who Are Overweight or Obese
|
Phase 1/Phase 2 | |
| Completed |
NCT04019561 -
A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.
|
Phase 2 | |
| Completed |
NCT01694849 -
Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)
|
Phase 2 | |
| Completed |
NCT02653300 -
A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH)
|
Phase 2 | |
| Completed |
NCT03517540 -
Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis
|
Phase 2 | |
| Withdrawn |
NCT05050721 -
Natural History of Non Alcoholic Fatty Liver Disease and Predictors of Advanced Fibrosis
|
||
| Active, not recruiting |
NCT04682600 -
The Sonic Incytes Liver Incytes System, Evaluation of Liver Fibrosis and Steatosis Versus MRE and MRI PDFF
|
N/A | |
| Enrolling by invitation |
NCT01950884 -
Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis
|
Phase 4 | |
| Completed |
NCT04483947 -
A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients
|
Phase 1 | |
| Completed |
NCT02927314 -
A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease
|
Phase 2 | |
| Active, not recruiting |
NCT02612662 -
A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects
|
Phase 1 | |
| Recruiting |
NCT06168383 -
To Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH) .
|
Phase 2 | |
| Terminated |
NCT02605616 -
Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)
|
Phase 2 | |
| Completed |
NCT02158351 -
Gut Microbiota and Modulation of Liver Damage in NAFLD
|
||
| Recruiting |
NCT03151473 -
Longitudinal Observational Study Of Chinese With NAFLD/NASH
|
||
| Recruiting |
NCT04820036 -
A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG)
|
N/A | |
| Recruiting |
NCT05553470 -
Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant
|
Phase 1 | |
| Recruiting |
NCT04639414 -
Combined Active Treatment in Type 2 Diabetes With NASH
|
Phase 4 | |
| Withdrawn |
NCT04607655 -
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis
|
Phase 1/Phase 2 |